{
    "organizations": [],
    "uuid": "a8ede2a3676e590141db911dcbf344f5a5fd0bec",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-invivo-therapeutics-receives-fda-a/brief-invivo-therapeutics-receives-fda-approval-for-controlled-trial-of-the-neuro-spinal-scaffold-idUSASB0C9FI",
    "ord_in_thread": 0,
    "title": "BRIEF-Invivo Therapeutics Receives FDA Approval For Controlled Trial Of The Neuro-Spinal Scaffold™",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Invivo Therapeutics Holdings Corp :\n* INVIVO THERAPEUTICS RECEIVES FDA APPROVAL FOR PIVOTAL, RANDOMIZED, CONTROLLED TRIAL OF THE NEURO-SPINAL SCAFFOLD™ IN PATIENTS WITH ACUTE SPINAL CORD INJURY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-08T21:18:00.000+02:00",
    "crawled": "2018-03-09T14:54:35.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "invivo",
        "therapeutic",
        "holding",
        "corp",
        "invivo",
        "therapeutic",
        "receives",
        "fda",
        "approval",
        "pivotal",
        "randomized",
        "controlled",
        "trial",
        "patient",
        "acute",
        "spinal",
        "cord",
        "injury",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}